Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Invitae | RCV000690017 | SCV000817693 | uncertain significance | Colorectal cancer, susceptibility to, 10 | 2023-03-26 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt POLD1 protein function. ClinVar contains an entry for this variant (Variation ID: 569400). This variant has not been reported in the literature in individuals affected with POLD1-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces tyrosine, which is neutral and polar, with serine, which is neutral and polar, at codon 936 of the POLD1 protein (p.Tyr936Ser). |
| Ambry Genetics | RCV003163140 | SCV003857566 | uncertain significance | Hereditary cancer-predisposing syndrome | 2023-01-06 | criteria provided, single submitter | clinical testing | The p.Y936S variant (also known as c.2807A>C), located in coding exon 21 of the POLD1 gene, results from an A to C substitution at nucleotide position 2807. The tyrosine at codon 936 is replaced by serine, an amino acid with dissimilar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |